FCGR3B and myelodysplastic syndrome: Consistent with our findings, both CD45 and CD16 are markers of certain hemolytic disorders (paroxysmal sleep hemoglobinuria) [29–31], and CD16 is a marker of certain hematologic neoplasms (myelodysplastic syndromes) [32].